Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib, Tamoxifen, and Cisplatin in Stage III Melanoma
NCT00492505Phase 2Unknown
- Sponsor
- San Diego Pacific Oncology & Hematology Associates
- Start
- Apr 2007
- Primary completion
- Dec 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sorafenib in cutaneous melanoma (CM), sponsored by San Diego Pacific Oncology & Hematology Associates. Primary endpoints: Relapse-Free Survival, Overall Survival and 1 more. Status: unknown.
02
Drugs
sorafenib
03
Conditions
cutaneous melanoma (CM)
Beyond the preview
Go deeper on NCT00492505.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00492505.